You are here

A Study Of PF-05212384 Plus Irinotecan Vs Cetuximab Plus Irinotecan In Patients With KRAS And NRAS Wild Type Metastatic Colorectal Cancer

Last updated on February 20, 2019

FOR MORE INFORMATION
Study Location
CBCC Global Research, Inc. at Comprehensive Blood and Cancer Center
Bakersfield, California, 93309 United States
Contact
1-800-718-1021
Eligibility criteria
Condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Metastatic Colorectal Cancer
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
18 + years
Inclusion criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- KRAS and NRAS wild type metastatic colorectal cancer

- Progression following treatment for colorectal cancer with irinotecan, oxaliplatin and
fluoropyrimidine therapy in the metastatic setting.

- Eastern Cooperative Oncology Group [ECOG] Performance Status of 0, 1, or 2

- At least one measurable lesion by Response Evaluation Criterion in Solid Tumors
[RECIST]

Exclusion criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details

- More than 2 prior cytotoxic chemotherapy regimens for metastatic colorectal cancer.

- Prior treatment with a PI3K, mTOR, AKT or EGFR inhibitor

- Patients who have discontinued treatment with prior irinotecan therapy due to
toxicity.

- Prior radiation to the pelvis or abdomen

- Patients with history of interstitial lung disease.

NCT01925274
Pfizer
Terminated
A Study Of PF-05212384 Plus Irinotecan Vs Cetuximab Plus Irinotecan In Patients With KRAS And NRAS Wild Type Metastatic Colorectal Cancer

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

call now

Try a new search

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.

Based on your search, you may also be interested in

Unresectable or Metastatic Colorectal Cancer
NCT00668863
All Genders
20+
Years
Multiple Sites
Metastatic Colorectal Cancer
NCT00457691
All Genders
18+
Years
Multiple Sites

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting the study website. Please see the references below:

BY PHONE

Pfizer Clinical Trials Contact Center

1-800-718-1021

BY EMAIL

Contact

[email protected]

Call Now